Croma-Pharma announces partnership with Megalabs
Croma-Pharma announces partnership with Megalabs, bringing high-performance aesthetic products to the entire Latin American region
Croma confirms the divestiture of its affiliate in Brazil to Megalabs with the closing of the contract on March 12, 2024.
The contractual agreement includes the distribution rights for the rest of Latin America and the Caribbean region for hyaluronic acid fillers, polynucleotide injectables, Croma’s extensive skincare portfolio as well as all Croma’s future technologies.
